Saxenda [Liraglutide 18mg/3mL] – Novo Nordisk

Description and Effects

Saxenda (Liraglutide) [6 mg/mL, 3 mL Pen, Novo Nordisk] is a GLP-1 receptor agonist designed to support weight management by acting on appetite regulation and satiety centers in the brain. It helps reduce hunger, increases feelings of fullness, and supports better control of daily calorie intake when combined with diet and physical activity.

Product Benefits

• Appetite Reduction : Helps decrease hunger and cravings throughout the day.
• Increased Satiety : Promotes a faster feeling of fullness after meals.
• Weight Management Support : Assists in progressive fat loss when combined with a structured nutrition plan.
• Metabolic Regulation : Supports improved glycemic control and metabolic balance.

Usage Instructions

• Recommended Dosage & Titration : Saxenda is typically used as a once-daily subcutaneous injection with gradual dose escalation to improve tolerance:
  • Week 1 : 0.6 mg daily
  • Week 2 : 1.2 mg daily
  • Week 3 : 1.8 mg daily
  • Week 4 : 2.4 mg daily
  • Week 5 onward : 3.0 mg daily (maintenance dose if tolerated)
• Injection Method : Administer subcutaneously in the abdomen, thigh, or upper arm, rotating injection sites regularly.

Precautions and Well-Being

• Potential Side Effects : May include nausea, digestive discomfort, reduced appetite, or mild fatigue during the initial adjustment phase.
• Tolerance Management : Dose should be increased gradually to minimize gastrointestinal effects.
• Hydration and Nutrition : Maintain adequate hydration and balanced nutrition to support adaptation.
• Proper Handling : Store and use the pen according to medical storage recommendations and always use sterile injection practices.